Starpharma has been granted a patent for dendrimers featuring a core unit, multiple generations of lysine residues, and terminal groups with cabazitazel and PEG. The patent includes pharmaceutical compositions and methods for using these dendrimers in cancer therapy, along with processes for their production. GlobalData’s report on Starpharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Starpharma, was a key innovation area identified from patents. Starpharma's grant share as of July 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Dendrimers for cancer therapy and pharmaceutical compositions
The granted patent US12071517B2 outlines a process for producing a therapeutically effective amount of a dendrimer or its pharmaceutically acceptable salt. The core component of the dendrimer is defined as a core unit (C), which serves as the foundational structure for the dendrimer's development. The claims emphasize the importance of the core unit in the overall efficacy of the dendrimer as a therapeutic agent, although specific details regarding the composition of the core unit are not provided in the excerpt.
Additionally, the patent specifies characteristics of the terminal groups associated with the dendrimer. Claim 2 addresses the first terminal groups (T1), indicating that their specific properties or configurations are relevant to the dendrimer's functionality. Claim 3 further elaborates on the second terminal groups, suggesting that these groups also play a critical role in the therapeutic effectiveness of the dendrimer. The claims collectively highlight the significance of both the core unit and the terminal groups in the design and application of dendrimers in pharmaceutical contexts.
To know more about GlobalData’s detailed insights on Starpharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
